Active: new fund Jul 2026 Verified 4 Nov 2026
TCGX
Science-driven investment firm focused on disruptive medicines, with a private portfolio. Based in Palo Alto, CA.
- Type
- VC firm
- Location
- Palo Alto, California, United States
- Backs
- Biotech and pharma
- Sectors
- Biotech, Healthtech and life sciences
- Fund size / AUM
- $600M TCGX Asia Life Sciences Fund I (Form D offering, 2026)
- Latest fund or filing
- 7 Oct 2026
- Portfolio mix
- Biotech and pharma 96%; Medtech and digital health 4% (n=25)
- Website
- tcgcrossover.com
Fund filings (SEC Form D)
- Latest fund on file
- TCGX Asia Life Sciences Fund I
- Filed
- 7 Oct 2026 (new notice)
- Fund size
- $600M (total offering)
- Fund vehicles filed in the last 12 months
- 1 (includes feeder and parallel vehicles)
See this fund's filings on SEC EDGAR
Contacts on file
For TCGX, the paid file holds: 8 named decision-makers with roles; firm contact email (domain checked).
Get US Complete, $197 Free sample
One-time payment. No subscription. No account.
Notable investments
AdarxAdcendoAffiniatxAktisoncologyAlkeuspharma
Sources
- www.sec.gov/Archives/edgar/data/2140843/000214084326000003/
- tcgcrossover.com/
- tcgcrossover.com/contact/
- tcgcrossover.com/our-team/
Last checked 4 Nov 2026. Is something wrong? Tell us.
Appears in 15 lists
Biotech investors in Silicon Valley (48)Biotech investors in the San Francisco Bay Area (88)Healthtech investors in Silicon Valley (91)Biotech investors in California (108)Healthtech investors in the San Francisco Bay Area (182)Healthtech investors in California (240)Biotech venture capital firms in the US (297)Venture capital firms in Silicon Valley (341)Biotech investors (484)Healthtech venture capital firms in the US (709)Venture capital firms in the San Francisco Bay Area (768)Venture capital firms in California (1,038)Healthtech investors (1,207)Active venture capital firms in the US (1,574)Venture capital firms in the US (2,975)